I read with interest the consensus guidelines on chronic urticaria by Steven KW Chow and colleagues [1] but have reservations with the statement that angiotensin converting enzyme inhibitors (ACEIs) should usually be avoided in chronic urticaria with or without angioedema. Although the EAACI/ GALEN/EDF/WAO position paper does allude to the fact that ACEIs come second to non-steroidal anti-infla...

BACKGROUND Several studies have reported the clinical effects of long-term treatment with cardioprotective medications in patients with lower limb peripheral arterial disease (PAD) in terms of reducing cardiovascular morbidity and mortality. A number of these studies investigated the clinical effect of angiotensin converting enzyme inhibitors (ACEIs) on walking distance in this group of patient...

ABSTRACT Background Per the guidelines established by European Society of Cardiology (ESC) for diagnosing and managing chronic acute heart failure, Sacubitril/Valsartan, Empagliflozin, Dapagliflozin are suggested to replace an angiotensin-converting enzyme (ACE) inhibitor significantly minimize failure (HF) associated risks including hospitalization possible death HF ambulatory patients with re...

Abstract Aims Left ventricular pressure overload is connected with cardiac renin–angiotensin system activation, which may lead to myocardial fibrosis and poorer clinical outcomes. Hypertensive patients symptomatic, severe aortic stenosis (AS) undergoing transcatheter valve implantation (TAVI) in the EffecTAVI registry were evaluated for association between baseline treatment angiotensin-convert...

OBJECTIVES To evaluate the effect of cardiologist care on adherence to evidence-based secondary prevention medications, mortality and readmission within 6 months of discharge in patients with heart failure (HF). DESIGN Retrospective observational study based on administrative data. SETTING Local Healthcare Authority (LHA) of Bologna, one of the largest LHAs of Italy with ~870 000 inhabitant...

BACKGROUND Several international studies suggest inequity in access to evidence-based heart failure (HF) care. Specifically, studies of ACE inhibitors (ACEIs) point to reduced ACEI access related to female sex, old age and socioeconomic position. Thus far, most studies have either been rather small, lacking diagnostic data, or lacking the possibility to account for several individual-based soci...

Importance The chronic receipt of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications associated with COVID-19 produce worse clinical outcomes. Objective To conduct an updated comprehensive systematic review meta-analysis comparing mortality severe adverse events (AEs) vs nonreceipt ACEIs or ARB...